Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | JAVELIN Renal 101: DepOR & outcomes in RCC

Martin Voss • 16 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Antibodies Avelumab Checkpoint Inhibitors
JAVELIN Renal 101

Martin Voss, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the depth of response (DepOR) analysis from the JAVELIN Renal 101 trial (NCT02684006), and the correlation with clinical outcomes in renal cell cancer (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Martin Voss

2:14
Individualizing RCC treatment
Martin Voss • 16 Feb 2020
2:14
Biomarkers in RCC
Martin Voss • 16 Feb 2020

Related Videos

6:36
How can we reduce disparities in prostate cancer in sub-Saharan Africa?
Onyeanunam Ekeke • 22 Apr 2024
6:26
Managing rising rates of prostate cancer in Africa
Onyeanunam Ekeke • 22 Apr 2024
1:51
Management of biochemical recurrence in prostate cancer
Jason Efstathiou • 30 Apr 2024
8:12
Unmet needs in high-risk localized and advanced prostate cancer
Jason Efstathiou • 30 Apr 2024
The content of VJOncology is intended for healthcare professionals